Osteomalacia
Methodology & AI Transparency ⓘ
Osteomalacia Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Osteomalacia is an ICD-10-CM indexed diagnosis (M83.9) within Osteoarthritis, Gout & Joint Pain.
- 2 Real-world patient consensus: Federal ICD-10-CM code M83.9 categorizes Osteomalacia under Osteoarthritis, Gout & Joint Pain.
- 3 Typical cash cost range: Primary evaluation for Osteomalacia incorporates synovial fluid crystal/cell in Osteomalacia (M83.9: analysis when effused) and symptom diary review.
- 4 Top reported side effects / signs: Longitudinal Osteomalacia monitoring tracks hs-CRP & Erythrocyte in Osteomalacia (M83.9: Sedimentation Rate) toward hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M83.9).
Ask our AI Specialists anything about Osteomalacia
What Is Osteomalacia?
Osteomalacia is an ICD-10-CM indexed diagnosis (M83.9) within Osteoarthritis, Gout & Joint Pain. Clinical evaluation centers on synovial fluid crystal/cell in Osteomalacia (M83.9: analysis when effused) alongside serial hs-CRP & Erythrocyte in Osteomalacia (M83.9: Sedimentation Rate) tracking (hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M83.9)) to guide individualized care.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Osteomalacia (M83.9) center on low-grade synovial metalloproteinase in Osteomalacia (M83.9: release). targeted arthritis & joints interventions aim to normalize hs-CRP & Erythrocyte in Osteomalacia (M83.9: Sedimentation Rate).
Common Symptoms & Clinical Signs
- • Presentation of Osteomalacia (M83.9): activity-related deep aching in Osteomalacia (M83.9: joint pain in)
- • Secondary Osteomalacia clinical sign: brief morning joint in Osteomalacia (M83.9: stiffness)
- • Symptom flares in Osteomalacia correlating with hs-CRP & Erythrocyte in Osteomalacia (M83.9: Sedimentation Rate) deviation outside hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M83.9)
- • Functional arthritis & joints impact requiring synovial fluid crystal/cell in Osteomalacia (M83.9: analysis when effused) evaluation (M83.9)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Osteomalacia Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | M83.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Osteoarthritis, Gout & Joint Pain | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: hs-CRP & Erythrocyte in Osteomalacia (M83.9: Sedimentation Rate) | hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M83.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Weight-Bearing Joint Radiograph [Osteomalacia M83.9] | Preserved joint-space width (M83.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Uric Acid in Osteomalacia (M83.9: (Gout Target)) | < 6.0 mg/dL (< 5.0 mg/dL with tophi) (M83.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Osteomalacia
Treatment selection for Osteomalacia depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Osteomalacia)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Age on the real-world benefits and safety of peficitinib (ASP015K) for the Peficitinib was efficacious in adult Asian RA patients of all ages. Modern rheumatology • 2022-07-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 34850095 ↗ |
| Can This Approach Help? Inside the Latest Research on Efficacy of baricitinib in patients with moderate-to-severe autoimmune joint pain Treatment with baricitinib 4 mg demonstrated efficacy for up to 3 years and was well tolerated. Rheumatology (Oxford, England) • 2021-05-14 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 33200220 ↗ |
| What the Latest Evidence Really Says About Association between statin use and incidence or progression of wear-and-tear Statin use may not be associated with a lower risk of incidence and progression of OA, regardless of joint site. Osteoarthritis and cartilage • 2020-09-15 • Meta-Analysis | Multi-cohort | 86/100 | PMID 32360737 ↗ |
| Can This Approach Help? Inside the Latest Research on Exploratory analysis of the potential disconnect between objective inflammatory There is a potential disconnect between objective measures of inflammation and clinical outcome responses in patients with axSpA. RMD open • 2024-08-28 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 39209369 ↗ |
Osteomalacia Patient Community & “People Like Me” Threads
Filter Osteomalacia community threads and patient logs by age, biological sex, dosage, and treatment duration.